China Universal Asset Management Co. Ltd. Has $596,000 Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

China Universal Asset Management Co. Ltd. increased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 10.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 11,128 shares of the company’s stock after buying an additional 1,095 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Janux Therapeutics were worth $596,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Janux Therapeutics by 202.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after acquiring an additional 156,675 shares in the last quarter. Algert Global LLC acquired a new position in shares of Janux Therapeutics during the 3rd quarter worth approximately $1,112,000. Ally Bridge Group NY LLC bought a new position in shares of Janux Therapeutics during the third quarter worth approximately $4,943,000. FMR LLC increased its holdings in shares of Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after buying an additional 38,490 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Activity

In other news, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the transaction, the chief executive officer now owns 242,054 shares in the company, valued at approximately $16,217,618. The trade was a 5.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares of the company’s stock, valued at $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 83,334 shares of company stock valued at $4,731,520 over the last quarter. 29.40% of the stock is owned by company insiders.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $43.48 on Monday. The company’s 50 day moving average price is $51.60 and its two-hundred day moving average price is $48.45. The firm has a market capitalization of $2.28 billion, a P/E ratio of -37.16 and a beta of 3.23. Janux Therapeutics, Inc. has a fifty-two week low of $7.79 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s quarterly revenue was down 82.6% on a year-over-year basis. On average, analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on JANX shares. HC Wainwright raised their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th. BTIG Research boosted their target price on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Finally, William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.